ASO Author Reflections: High Stromal TGFBI is a Useful Predictive Marker for Nivolumab in Non-small Cell Lung Cancer

  • Nobuhiro NakazawaEmail author
  • Takehiko Yokobori
  • Andrei Turtoi
  • Ken Shirabe
ASO Author Reflections



None of the authors have conflicts of interest to disclose.


  1. 1.
    Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 2015;373(2):123–135.CrossRefGoogle Scholar
  2. 2.
    Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 2015;373(17):1627–1639.CrossRefGoogle Scholar
  3. 3.
    Mariathasan S, Turley SJ, Nickles D, et al. TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature 2018;554(7693):544–548.CrossRefGoogle Scholar
  4. 4.
    Skonier J, Neubauer M, Madisen L, Bennett K, Plowman GD, Purchio AF. cDNA cloning and sequence analysis of beta ig-h3, a novel gene induced in a human adenocarcinoma cell line after treatment with transforming growth factor-beta. DNA Cell Biol 1992;11(7):511–522.CrossRefGoogle Scholar
  5. 5.
    Nakazawa N, Yokobori T, Kaira K, et al. High stromal TGFBI in lung cancer and intratumoral CD8-positive T cells were associated with poor prognosis and therapeutic resistance to immune checkpoint inhibitors. Ann Surg Oncol 2019-06-1409. 2019.

Copyright information

© Society of Surgical Oncology 2019

Authors and Affiliations

  • Nobuhiro Nakazawa
    • 1
    Email author
  • Takehiko Yokobori
    • 2
  • Andrei Turtoi
    • 3
  • Ken Shirabe
    • 1
  1. 1.Department of General Surgical Science, Graduate School of MedicineGunma UniversityMaebashiJapan
  2. 2.Department of Innovative Cancer Immunotherapy, Graduate School of MedicineGunma UniversityMaebashiJapan
  3. 3.Tumor Microenvironment LaboratoryInstitut de Recherche en Cancérologie de Montpellier, INSERM U1194MontpellierFrance

Personalised recommendations